📊 ACRV Key Takeaways
Is Acrivon Therapeutics, Inc. (ACRV) a Good Investment?
Acrivon is a pre-revenue biotech company with a solid balance sheet ($95.5M equity, $34.1M cash) but faces critical runway constraints. Operating cash burn of -$20.5M annually provides only ~1.6 years of liquidity without additional funding or revenue generation. Without visible commercialization milestones or clear clinical pipeline data, the company presents unacceptable execution risk relative to available runway.
Acrivon Therapeutics shows the classic profile of a pre-revenue biotech with no operating income, persistent losses, and deeply negative free cash flow. Its balance sheet is currently clean with strong liquidity and no long-term debt, but the annual cash burn relative to cash on hand suggests funding risk unless development milestones improve or additional capital is raised.
Acrivon Therapeutics, Inc. Key Strengths (ACRV)
- Strong balance sheet with $95.5M stockholders' equity
- Excellent liquidity position (8.98x current ratio) with minimal debt burden
- Recently reported financial data (Q1 2026)
- Strong near-term liquidity with 8.75x current and quick ratios
- Debt-free capital structure reduces financial leverage risk
- Equity base remains sizable at $128.60M versus only $16.70M of liabilities
ACRV Stock Risks: Acrivon Therapeutics, Inc. Investment Risks
- Zero revenue generation with no clear commercialization timeline
- Annual operating cash burn of -$20.5M limits financial runway to ~1.6 years
- Typical biotech risks: drug development, regulatory approval, market competition unquantified
- Significant negative cash flow with minimal capital expenditure suggests development-stage struggles
- No revenue base, leaving the business fully dependent on pipeline progress and external financing
- High annual operating and free cash flow burn relative to $35.41M cash balance
- Profitability remains weak with negative ROE of -45.8% and ROA of -40.6%
Key Metrics to Watch
- Quarterly operating cash flow trend and cash balance depletion rate
- Achievement of clinical milestones and regulatory approvals
- Capital raise announcements and dilution impact on equity holders
- Cash runway relative to operating cash burn
- Any emergence of collaboration revenue, milestone payments, or narrowing net loss
Acrivon Therapeutics, Inc. (ACRV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.98x current ratio provides a solid financial cushion.
ACRV Profit Margin, ROE & Profitability Analysis
ACRV vs Healthcare Sector: How Acrivon Therapeutics, Inc. Compares
How Acrivon Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Acrivon Therapeutics, Inc. Stock Overvalued? ACRV Valuation Analysis 2026
Based on fundamental analysis, Acrivon Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Acrivon Therapeutics, Inc. Balance Sheet: ACRV Debt, Cash & Liquidity
ACRV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Acrivon Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.38 indicates the company is currently unprofitable.
ACRV Revenue Growth, EPS Growth & YoY Performance
Acrivon Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ACRV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Acrivon Therapeutics, Inc. (CIK: 0001781174)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ACRV
What is the AI rating for ACRV?
Acrivon Therapeutics, Inc. (ACRV) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACRV's key strengths?
Claude: Strong balance sheet with $95.5M stockholders' equity. Excellent liquidity position (8.98x current ratio) with minimal debt burden. ChatGPT: Strong near-term liquidity with 8.75x current and quick ratios. Debt-free capital structure reduces financial leverage risk.
What are the risks of investing in ACRV?
Claude: Zero revenue generation with no clear commercialization timeline. Annual operating cash burn of -$20.5M limits financial runway to ~1.6 years. ChatGPT: No revenue base, leaving the business fully dependent on pipeline progress and external financing. High annual operating and free cash flow burn relative to $35.41M cash balance.
What is ACRV's revenue and growth?
Acrivon Therapeutics, Inc. reported revenue of N/A.
Does ACRV pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
Where can I find ACRV SEC filings?
Official SEC filings for Acrivon Therapeutics, Inc. (CIK: 0001781174) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACRV's EPS?
Acrivon Therapeutics, Inc. has a diluted EPS of $-0.49.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ACRV's fundamental grade?
Based on our AI fundamental analysis in June 2026, Acrivon Therapeutics, Inc. has a C grade with 70% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ACRV stock overvalued or undervalued?
Valuation metrics for ACRV: ROE of -19.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ACRV's AI grade for 2026?
Our dual AI analysis gives Acrivon Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACRV's free cash flow?
Acrivon Therapeutics, Inc.'s operating cash flow is $-20.5M, with capital expenditures of $14.0K.
How does ACRV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -19.9% (avg: 15%), current ratio 8.98 (avg: 2).